Researchclopedia
Research
Researchers
Institutions
Topics
Submit
About
Search...
⌘
K
Command Palette
Search for a command to run...
Back to research
A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzyl-3-carboxyazetidine Sphingosine-1-phosphate-1 Receptor Agonists
2004
88 citations
Journal Article
green Open Access
Field-Weighted Citation Impact:
1.99
Mark Rosenbach
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
James A. Milligan
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Gan-Ju Shei
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Stephen A. Parent
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Gary Chrebet
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
James D. Bergstrom
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Deborah Card
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Marc Ferrer
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Peter Hodder
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Berta Strulovici
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Hugh Rosen
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Suzanne Mandala
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzyl-3-carboxyazetidine Sphingosine-1-phosphate-1 Receptor Agonists | Researchclopedia